Abstract
Objective: To identify metabolic syndrome (MetS) clustering patterns, examine transitions between classes from perimenopausal to postmenopausal stages, and identify factors associated with these transitions. Methods: This secondary analysis used data from 1,104 women in the Korean Genome Epidemiology Study, a population-based longitudinal cohort. Latent class analysis was conducted for perimenopausal and postmenopausal stages, and latent transition analysis class changes. Age at menopause, white blood cell count, and homeostasis model assessment of insulin resistance (HOMA-IR) were examined as predictors. Results: Four classes were identified in the perimenopausal stage: metabolic-diabetic, metabolic-hypertensive, low high-density lipoprotein cholesterol (HDL-c), and non-MetS. Five classes were identified in the postmenopausal stage: treated-hypertensive, metabolic-hypertensive, high-risk, low HDL-c, and non-MetS. Approximately 40% of women changed their classes during the menopause transition. The metabolic-diabetic group showed a markedly higher likelihood of progression to the high-risk group (88.3%). In the metabolic-hypertensive group at the perimenopausal stage, higher HOMA-IR was associated with increased transitions to low the HDL-c (odds ratio [OR]: 51.37, 95% CI: 15.27-172.78) and high-risk (OR: 78.10, 95% CI: 19.16-318.30) classes. Later menopause reduced the likelihood of remaining in (OR: 0.10, 95% CI: 0.02-0.50) or progressing to high-risk (OR: 0.05, 95% CI: 0.01-0.43) in the metabolic-hypertensive group but increased the probability of transitioning to treated-hypertensive in women in the non-MetS group (OR: 1.48, 95% CI: 1.13-1.94). Conclusions: Metabolic risk profiles shift substantially during menopause. Targeted interventions, especially for high-risk groups before menopause, and the inclusion of simple insulin resistance markers such as HOMA-IR in screening may improve prevention and management.
Affiliated Institutions
Related Publications
National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study
Background— To assess the utility of clinical definitions of the metabolic syndrome (MetS) to identify individuals with increased cardiovascular risk, we examined the relation b...
Central Obesity as a Precursor to the Metabolic Syndrome in the AusDiab Study and Mauritius
Evidence from epidemiologic studies that central obesity precedes future metabolic change and does not occur concurrently with the appearance of the blood pressure, glucose, and...
Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey
Background— The combination of cardiovascular risk factors known as the metabolic syndrome is receiving increased attention from physicians, but data on the syndrome’s associati...
Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol
OBJECTIVE—To assess the effect of insulin resistance and the benefit of the fibrate, gemfibrozil, on the incidence of major cardiovascular events in subjects with low HDL choles...
Estrogen Replacement Therapy and Prognosis after First Myocardial Infarction
The effects of estrogen replacement therapy on prognosis in women with established coronary disease remain uncertain. The authors conducted a retrospective cohort study of 726 w...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1097/gme.0000000000002689